Compare RIVN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | INSM |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 23.0B |
| IPO Year | 2021 | 2000 |
| Metric | RIVN | INSM |
|---|---|---|
| Price | $16.50 | $95.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 24 |
| Target Price | $17.74 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 28.3M | 3.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.54 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,387,000,000.00 | N/A |
| Revenue This Year | $36.51 | $182.31 |
| Revenue Next Year | $63.08 | $65.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.39 | N/A |
| 52 Week Low | $11.57 | $90.39 |
| 52 Week High | $22.69 | $212.75 |
| Indicator | RIVN | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 38.07 |
| Support Level | $14.49 | $90.39 |
| Resistance Level | $17.71 | $166.81 |
| Average True Range (ATR) | 1.14 | 5.25 |
| MACD | 0.00 | 0.88 |
| Stochastic Oscillator | 49.61 | 32.99 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company plans to begin selling a midsize SUV in 2026. Total deliveries were over 42,000 in 2025. Rivian is also developing autonomous driving software to be used in its vehicles and for robotaxis on the Uber ride-hailing network.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.